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Detection of EGFR Gene Mutations Using the Wash Fluid
of CT-Guided Biopsy Needle in NSCLC Patients
Hiroki Otani, MD,* Shinichi Toyooka, MD,* Junichi Soh, MD,* Hiromasa Yamamoto, MD,*
Hiroshi Suehisa, MD,* Naruyuki Kobayashi, MD,* Hideo Gobara, MD,† Hidefumi Mimura, MD,†
Katsuyuki Kiura, MD,‡ Yoshifumi Sano, MD,* Susumu Kanazawa, MD,† and Hiroshi Date, MD§
Introduction: In this study, we examined whether epidermal growth
factor receptor (EGFR) mutations were detectable using a polymer-
ase chain reaction-based assay and wash fluid of computed tomog-
raphy (CT)-guided lung biopsy needles.
Methods: DNA was extracted from wash fluid of CT-guided biopsy
needles of 53 lung tumors (as diagnosed according to the results of
the CT-guided biopsies). EGFR mutations, specifically exon19 de-
letions and exon21 L858R mutations, were examined using a mu-
tant-enriched polymerase chain reaction assay. We also examined
the presence of EGFR mutations in 26 surgically resected tumor
specimens and compared the results with those obtained for the
corresponding wash fluid samples.
Results: The amount of DNA obtained for the wash fluid of the
CT-guided biopsy needles ranged from 35 to 2360 ng. There were
no significant differences in the amount of extracted DNA according
to the tumor characteristics, including tumor size and the percentage
of ground glass opacity. Thirty-four of the 53 lung tumor samples
were histologically diagnosed as non-small cell lung cancer
(NSCLC). Exon19 deletions and exon21 L858R mutations in EGFR
were detected in 4 (12%) and 13 (38%) of 34 NSCLC cases,
respectively. No EGFR mutations were found in the non-NSCLC
cases. The EGFR mutation status in the wash fluid samples was
consistent with those obtained for all 26 corresponding surgical
specimens.
Conclusion: Our results indicate that EGFR mutations can be
detected using wash fluid of CT-guided biopsy needles. In this
manner, the DNA genotype can be determined even in extremely
small clinical specimens using highly sensitive assays.
Key Words: EGFR, Mutant-enriched PCR, CT-guided lung biopsy,
NSCLC.
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Lung cancer is the leading cause of death from cancerworldwide and has a unfavorable prognosis.1 Primary lung
cancer is classified into two major histologic categories,
non-small cell lung cancer (NSCLC) and small cell lung
cancer,1 and various therapeutic strategies, including molec-
ular targeting therapy, have been developed to improve the
survival of lung cancer patients.
Epidermal growth factor receptor (EGFR) is a trans-
membrane tyrosine kinase (TK) receptor that is frequently
expressed in various kinds of epithelial tumors. The signaling
pathways of activated EGFR are involved in cancer cell
proliferation, apoptosis, angiogenesis, invasion, and metasta-
sis,2,3 suggesting that EGFR is an appropriate target for
molecular-targeting therapy.
In 2004, mutations in the EGFR gene were discov-
ered.4,5 EGFR mutations are exclusively present in NSCLC
patients, especially in women, patients with adenocarcinoma,
and patients with a never smoking status.6,7 Of clinical
importance, common EGFR mutations (like the exon19 de-
letion and the exon21 point mutation at codon 858) are
significantly associated with tumor response to EGFR-TK
inhibitors (EGFR-TKIs), like gefitinib and erlotinib.4,5 Thus,
EGFR mutations are thought to be a useful predictive marker
of therapeutic response to EGFR-TKIs, suggesting that
EGFR mutation is an important clinical factor in the treat-
ment of patients with NSCLCs.
To develop a convenient and practical method of ex-
amining the EGFR mutation status, two factors are consid-
ered essential: the reliability of the assays and the types of
clinical samples used for analysis. Various assays with high
sensitivities have been developed for the detection of EGFR
mutations.8–11 Regarding clinical samples, small biopsied
specimens, pleural effusion or fluid, and serum DNA have
been demonstrated as appropriate specimens for genotyp-
ing.12,13 We previously developed a mutant-enriched poly-
merase chain reaction (PCR) assay for detecting the EGFR
exon19 deletion and the L858R mutation and successfully
used this assay to detect EGFR mutations in small clinical
samples, like computed tomography (CT)-guided biopsy
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samples and soluble DNA from pleural fluid.12 Because the
opportunity to obtain clinical samples for molecular analysis
is sometimes limited among patients in poor physical condi-
tion, it is important to determine what kinds of clinical
samples can be used for genotyping analysis.
CT-guided biopsies are often used to diagnose lung
tumors, especially when the tumor is small or exhibits
ground-glass opacity (GGO) features.14 Because tissue spec-
imens should be submitted to microscopic examination after
being formalin-fixed and embedded in paraffin, a multistep
process is required and DNA fragmentation often occurs
during the course of formalin fixation. To establish a more
convenient analytical procedure, we attempted to examine the
EGFR mutation status using wash fluid of CT-guided biopsy
needle, in which a small amount of tumor cells or small piece
of tissue usually remains. In this study, we investigated the
possibility of detecting EGFR mutations using wash fluid of
diagnostic CT-guided biopsy needle for lung tumors.
MATERIALS AND METHODS
Patients and Clinical Samples
We studied a total of 53 lung tumors that were diag-
nosed using CT-guided biopsies at Okayama University Hos-
pital. The locations of the tumors were as follows: 32 lung
tumors (61%) were located in the right lobe and 21 (39%)
tumors were located in the left lobe. The clinical factors were
evaluated according to age, sex, smoking status, and histol-
ogy. Twenty-two women and 31 men, whose ages ranged
from 51 to 85 years (median, 71 years), were examined.
Thirty tumor tissues were histologically diagnosed as adeno-
carcinoma, four tumors were diagnosed as squamous cell
carcinoma, and 19 tumors were diagnosed as other types (17
benign diseases and two small cell carcinomas) (Table 1).
The permission of the institutional review board and the
informed consent of each patient were obtained. Of the 36
tumors diagnosed histologically as cancer, 26 went on to
surgical resection and a piece of the resected tumors was
frozen at minus 80°C.
CT-Guided Biopsy and DNA Extraction
Experienced interventional radiologists performed the
CT-guided biopsies. All the biopsies were carried out accord-
ing to the standard protocol. The patients were placed in a
prone, supine, or lateral decubitus position, depending on the
localization of the lesion. After CT images with a section
thickness of 5 mm were obtained across the entire lesion, the
needle entry site was planned to avoid bullae and vascular
structures. After local anesthesia was administered, the oper-
ator inserted a 19-gauge Co-Axial Introducer needle (Medical
Device Technologies, INC., Gainesville, FL), the length of
which was either 4.2 or 10.2 cm, through the chest wall and
into the tumor. After the stylet was removed, the biopsy was
performed using a 20-gauge Super Core Biopsy Instrument
(Medical Device Technologies, INC.), the length of which
was either 9 or 15 cm, inserted through the Introducer needle.
After the CT-guided biopsy was performed 2 or 3 times to obtain
multiple specimens for histologic diagnosis, the specimens were
removed from the needle and were only used for pathologic
examination. Next, the needle was washed out using 1.2 ml of
phosphate buffered saline. The representative images of lung
tumors and CT-guided biopsies are shown in Figure 1.
After the wash fluid of CT-guided lung biopsy needle
was centrifuged and liquid component was removed, DNA
was extracted using the QIAmp DNA blood kit (Qiagen,
Valencia, CA), according to the manufacturer’s protocol. The
extracted DNA was dissolved in 50 L of buffer AE (Qia-
gen). DNAs of frozen resected tumors were isolated by
digestion with proteinase K and followed by phenol-chloro-
form extraction and ethanol precipitation. The concentration
of DNA was measured using NanoDrop ND-1000 (Nano-
Drop Technologies, Rockland, DE).
Mutational Analysis of EGFR in Wash Fluid of
CT-Guided Biopsy Needle
We analyzed samples by the mutant-enriched PCR
assay that was two-step PCR with intermittent restriction
digestion to selectively eliminate wild-type genes. The
mutant-enriched PCR assay is able to detect 1 mutant gene
of 2  103 wild-type genes in various clinical samples.
The primers and amplification conditions with detail of
protocol were described previously.12 While we measured
the concentration of DNA, we used 1 L out of 50 L of
eluted DNA regardless of its concentration as DNA tem-
plate for the first PCR.
We also analyzed the samples using a nonenriched PCR
assay as described previously.12 In brief, the common dele-
tions of exon19 were distinguished from the wild type based
on PCR product length polymorphisms. The L858R point
mutation was able to be detected using PCR-restriction frag-
ment length polymorphism with Sau96I digestion followed
by electropheresis.
Direct sequencing for EGFR exon19 and 21 was done
using Applied Biosystems PRISM dye terminator cycle se-
quencing method (Applied Biosystems, Foster City, CA) with
ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).15







Smoking history Never 21
Ever 32
Histology Adenocarcinoma 30
Squamous cell carcinoma 4
Small cell carcinoma 2
Benign tumor 17
Tumor size (mm) 20 27
20 26
CT, computed tomography.
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Statistical Analyses
The differences of significance among categorized
groups were compared using 2 test or Fisher exact test
when appropriate. Two-sided p values less than 0.05 were
defined to be significant different. All statistical tests were
performed using the SPSS software (version11.0; SPSS
Inc., Chicago, IL).
RESULTS
Characteristics of Lung Tumors and Amount of
Extracted DNA
We classified the tumor size according to the major
diameter of the tumor on the CT slices. The tumors ranged in
size from 5.8 to 50.4 mm (median, 19.5 mm). Twenty-six
tumors were equal or larger than 20 mm in diameter, whereas
27 were less than 20 mm. The percentage of GGO lesion was
calculated using the major diameter of each tumor on lung
and mediastinal window of the same CT slice, 24 (71%) of
the 34 NSCLC tumors had the percentage of less than 50%,
whereas the remaining 10 (29%) had the percentage of equal
or more than 50%. The amount of DNA in the wash fluid
samples ranged from 35 to 2360 ng (median, 155 ng). The
relationship between the tumor characteristics including tu-
mor size, histology, and GGO lesion (only for NSCLC) and
the amount of DNA obtained was examined in the lung
cancer. No significant relationships between the amount of
DNA obtained and examined tumor characteristics were ob-
served.
The Relationship Between Patients’
Characteristics and EGFR Mutations
Among the wash fluid samples obtained for the CT-
guided biopsy needle, which were examined using a mutant-
enriched PCR assay, EGFR mutations were found in 17 (32%)
of the 53 lung tumors. These mutations comprised 4 exon19
deletions and 13 exon21 L858R mutations. All the mutations
TABLE 2. Relationship Between Clinical Features and EGFR
Mutation Status of 30 Lung Adenocarcinomas in Wash Fluid
of CT-Guided Biopsy Needle





Sex Male 17 (57) 3 4 10 0.071
Female 13 (43) 1 9 3
Smoking history Never 13 (43) 1 11 1 0.0008
Ever 17 (57) 3 2 12
Tumor size (mm) 20 14 (47) 2 7 5 0.48
20 16 (53) 2 6 8
GGO (%) 50 21 (70) 3 8 10 0.69
50 9 (30) 1 5 3
DNA for assay (ng) 3.1 14 (47) 2 6 6 1.0
3.1 16 (53) 2 7 7
CT, computed tomography; NSCLC, non-small cell lung cancer; GGO, ground-
glass opacity; EGFR, epidermal growth factor receptor.
FIGURE 1. The representative images of lung
tumors and computed tomography (CT)-guided
biopsies. A, 19.5  14.8 mm lung adenocarci-
noma in the S1 of right lung in patient #27. B,
After CT-guided biopsy was performed for lung
tumor of patient #27, the amount of DNA ob-
tained from the wash fluid of CT-guided biopsy
needle was 215 ng, and exon19 deletion muta-
tion in EGFR was detected. C, 16.4  8.8 mm
lung adenocarcinoma in the S3 of left lung in
patient #10. D, After CT-guided biopsy was per-
formed for lung tumor of patient #10, the
amount of DNA obtained from the wash fluid
was 160 ng, and exon21 L858R mutation in
EGFR was detected.
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were found in wash fluid samples from the patients diagnosed as
having lung adenocarcinoma (Table 2). Thus, subsequent anal-
yses were limited to the patients with lung adenocarcinoma.
EGFR mutations were significantly more frequent in never-
smokers than in ever-smokers (p  0.0008). Nevertheless,
EGFRmutations were not associated with sex, tumor size or the
percentage of GGO in this cohort. In addition, we examined the
relationship between the amount of DNA and EGFR mutations.
In all the lung tumors, the median DNA amount in the wash fluid
samples was 155 ng and one-fiftieth of the DNA (3.1 ng) was
applied for PCR assays, as mentioned above. EGFR mutations
were found in 8 (57.1%) out of 14 cases with an amount of less
than 3.1 ng and in 9 (56.3%) out of 16 cases with an amount of
3.1 ng or more, indicating that the presence of EGFR mutations
were not related to the obtained DNA amount. In addition,
among the EGFR mutation-positive cases, the minimum DNA
amount was 0.7 ng, suggesting that EGFR mutations could be
detected even when only a very small amount of DNA was
available in our system.
Corresponding surgically resected specimens were ob-
tained after CT-guided biopsy in 26 cases, 25 cases were
diagnosed as NSCLC and 1 case was small cell carcinoma.
EGFR mutations were detected in 14 cases, consisting of 3
cases with an exon19 deletion and 11 cases with an exon21
L858R mutation. The EGFR mutation status of the wash fluid
samples was consistent with that of the corresponding re-
sected specimens (Table 3).
Comparison of Mutant-Enriched and
Nonenriched PCR Assay and of PCR
Assays and Direct Sequencing
We also examined the EGFR mutation status in 53 lung
tumors using nonenriched PCR assay and compared the
results with those obtained by mutant-enriched PCR assay.
The exon19 deletion was detected in four tumors using
both assays. For the L858R point mutation, nonenriched
PCR assay detected in 8 of the 13 mutations (Figure 2). We
could not detect 29.4% of EGFR mutation using nonen-
riched PCR assay.
Direct sequencing was performed in 26 resected sam-
ples and corresponding wash fluid samples of CT-guided
biopsy needle. The results were consistent with nonenriched
PCR assay and no discrepancy between resected samples and
wash fluid samples of CT-guided biopsy needle (3 cases of
exon 19 deletions and 6 cases of L858R mutations). Exon19
deletions consisted of 2 cases of delE746-A750 and 1 case of
delL747-delT751.
TABLE 3. The Comparison EGFR Mutation Status in Wash




Exon19 Exon21 Wild Type
Wash fluid samples (53 in
total)
Adenocarcinoma 30 (57) 4 13 13
Squamous cell carcinoma 4 (7) 0 0 4
Small cell carcinoma 2 (4) 0 0 2
Benign tumor 17 (32) 0 0 17
Surgical samples (26 out
of 53)
Adenocarcinoma 22 (85) 3 11 8
Squamous cell carcinoma 3 (12) 0 0 3
Small cell carcinoma 1 (4) 0 0 1
Benign tumor 0 (0) 0 0 0
EGFR, epidermal growth factor receptor.
FIGURE 2. Comparison of nonenriched poly-
merase chain reaction (PCR) assays with enriched
PCR assays in wash fluid of computed tomogra-
phy (CT)-guided biopsy samples. Exon19 dele-
tion and exon21 L858R mutation of epidermal
growth factor receptor (EGFR) was analyzed us-
ing DNA that was extracted from wash fluid of
CT-guided biopsy needle. A, Nonenriched PCR
assay for exon19 deletion. B, Mutant-enriched
PCR assay for exon19 deletion. C, Nonenriched
PCR assay for L858R mutation. D, Mutant-en-
riched PCR assay for L858R mutation. M, DNA
marker; C, CT-guided biopsy specimen; Mut,
mutant band; Wild, wild-type band; B, blank.
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DISCUSSION
In this study, we demonstrated that wash fluid of
CT-guided biopsy needle was useful for EGFR mutation
analyses. Although the amount of extracted DNA was small,
PCR amplification was successfully performed—enabling
the EGFRmutation status to be determined even in cases with
small nodules and GGO lesions.
Recent reports have shown that EGFR mutations in
NSCLC are associated with the sensitivity of the tumor to
EGFR-TKIs, suggesting that the EGFR mutation status has
important implications for the treatment of lung cancer.4,5
More than two-thirds of lung cancer cases are in advanced
stage, and the examination of gene mutations should be
performed using small amount of samples.16 Therefore, the
detection of EGFR mutations not only in surgical tissues, but
also in small clinical samples is an important issue. Previous
studies have shown no differences between the results of
EGFR mutation analyses using surgical samples and those
using biopsy samples, such as transbronchial needle aspira-
tions, ultrasound percutaneous biopsies, or pleural effu-
sions.17 In particular, we had focused on the effective use of
samples that are often discarded, like pleural fluid.18 In the
CT-guided biopsy, the obtained tissue is so small that whole
tissue is submitted to pathologic examination and should not
be used for gene analysis. Therefore, our effective usage of
needle after CT-guided biopsy supports the growing potential
of clinical materials from patients.
In the present study, the rates of EGFR mutation were
60% among adenocarcinoma lesions, consistent with the
finding of previous reports.6 As expected, a positive EGFR
mutation status was significantly associated with an adeno-
carcinoma histology and a never-smoking status. No discrep-
ancies in the EGFR mutation status were seen between the
wash fluid samples and the corresponding surgically resected
samples, which suggests that mutation analysis using wash
fluid samples is accurate. In addition, no mutations were
found in non-NSCLC lung tumor patients as reported,7 sug-
gesting the specificity of this strategy.
Our results indicated that about 30% of the EGFR
mutations were not detected using a nonenriched PCR assay.
Wash fluid collected from needles also contains nonmalig-
nant cells that may lower the detection sensitivity of assays.
Similar results were obtained using pleural fluid specimens in
our previous study,18 indicating that a highly sensitive assay
is mandatory to detect mutation in clinical specimens. Several
studies have reported unique assays to detect EGFR muta-
tions.8–11 These assays also have a markedly high sensitivity
and specificity and are considered appropriate for analyzing
small amount of clinical samples.
There are two major limitation of the mutant-enriched
PCR assay as described previously. (a) There is a risk of a
false-positive result, because the restriction site of wild-type
fragments may be destroyed by the erroneous replacement of
a critical nucleotide, for the high PCR cycle number. (b) The
aspect that this method can only be used to analyze specific
alterations containing a common mutation and it cannot
detect minor alterations such as mutations in exon 18, minor
deletions of exon 19 and exon 20 insertions.
In summary, we demonstrated the usefulness of wash
fluid samples collected from CT-guided biopsy needles for
the detection of EGFR mutations. Highly sensitive PCR-
based assays may enable the DNA genotypes of various
genes to be determined using only extremely small amount of
clinical specimens.
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